Last reviewed · How we verify
NCT03658408
4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy
Phase 2 trial testing 4-aminopyridine in Prostate Disease. Withdrawn.
30 October 2018
Quick facts
| Lead sponsor | University of Rochester |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Start date | 3 October 2018 |
| Primary completion | 30 October 2018 |
| Estimated completion | 30 October 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 4-aminopyridine — full drug profile →
- placebo
Conditions studied
- Prostate Disease — all drugs for Prostate Disease →
Sponsor
University of Rochester
Who can join
Adults 45 to 75, male only, with Prostate Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to see if the study drug 4-aminopyridine (4-AP) can help speed up the recovery of peripheral nerve injury after prostatectomy. 4-AP is a potassium channel blocker used to improve walking in multiple sclerosis patients. Investigators will measure the effect that 4-AP may have on the recovery of sexual function and urinary incontinence after prostatectomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03658408
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Disease
Currently open trials in the same condition.
- NCT07130708 — Exploring the Potential of Robotic Telesurgery in Remote Settings · NA · recruiting
- NCT06944743 — TURP Inpatient With Underactive Bladder With BOO · NA · recruiting
- NCT06636747 — High Resolution Diffusion Weighted Imaging in Prostate · recruiting
- NCT05682742 — Clinical Investigation of the da Vinci Surgical System · NA · active not recruiting
- NCT04288427 — 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy · NA · recruiting
Other University of Rochester trials
Trials by the same sponsor.
- NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
- NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
- NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
- NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
- NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03658408 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rochester
- Last refreshed: 2 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03658408.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing